Ironwood Pharmaceuticals, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. Unaudited results; dollar amounts below are in millions unless stated otherwise. Ironwood is a GI-focused company whose primary commercial product is LINZESS, marketed with partners. Results include continuing operations; its sGC business was spun off to Cyclerion in April 2019 and is presented as discontinued operations for the applicable prior-year period.
Financial performance and position
| Metric | Q3 2020 | Q3 2019 | First 9 months 2020 | First 9 months 2019 |
|---|---|---|---|---|
| Total revenue | $103.5 | $131.2 | $272.8 | $302.1 |
| Operating income | $45.6 | $65.9 | $91.6 | $70.5 |
| Net income (loss) | $34.4 | $20.6 | $63.0 | $(26.4) |
| Operating cash flow | Not separately presented for the quarter | $117.3 | $(28.2) continuing operations; $(16.9) including discontinued operations |
- Revenue and mix: Q3 revenue declined 21% year over year; nine-month revenue declined 10%. Collaborative-arrangement revenue was $103.5 million for Q3 and $267.3 million for nine months. API sales were zero in Q3 and $5.5 million year to date, versus $28.1 million in the prior-year nine-month period.
- Profitability: Operating margin was approximately 44% in Q3 and 34% for the first nine months, compared with approximately 50% and 23%, respectively, in 2019. Q3 net income rose despite lower revenue; nine-month net income benefited from the absence of the prior-year discontinued-operation loss.
- Cash and liquidity: Cash and cash equivalents were $307.6 million at September 30, 2020, up from $177.0 million at year-end 2019. Operating activities provided $117.3 million; investing activities used $1.8 million and financing activities provided $15.0 million. Management said available cash should fund projected operating needs at least through the next 12 months.
- Debt: Convertible-note principal totaled approximately $520.7 million: $120.7 million due 2022, $200 million due 2024 and $200 million due 2026. The balance-sheet carrying amount was $424.5 million, reflecting unamortized discounts and issuance costs. Notes are senior unsecured; stated cash coupons are 2.25%, 0.75% and 1.50%, respectively. Total liabilities also include $23.9 million of operating lease liabilities.
- Balance sheet: Total assets were $492.3 million and stockholders’ equity was $5.9 million, versus a $93.3 million deficit at year-end 2019. Current assets were $433.3 million and current liabilities $32.9 million.
Material changes versus the prior comparable period
- U.S. LINZESS collaboration revenue increased: Ironwood’s share of U.S. net profits rose by approximately $15.7 million in Q3 and $34.0 million for nine months, attributed to higher prescription demand and lower collaboration-related selling costs during the pandemic.
- Prior-year revenue included one-time license-related amounts: approximately $32.4 million under the amended AstraZeneca agreement and $10.0 million under the amended Astellas agreement. These items contributed to lower reported 2020 revenue comparisons. Lower API sales, particularly to Astellas in Japan, also reduced nine-month revenue.
- Research and development expense fell 21% in Q3 and 19% for nine months; selling, general and administrative expense fell 15% and 20%, respectively. The filing attributes reductions in part to lower development spending, facilities costs and costs associated with the 2019 separation.
- Prior-year comparisons included a $31.0 million debt-extinguishment loss, a $3.2 million lease-modification gain and, for the nine-month period, a $37.4 million loss from discontinued operations. These items make year-over-year net-income comparisons less directly comparable.
Outlook, commentary, risks and unusual items
- Pipeline setbacks: Ironwood discontinued IW-3718 after a Phase III trial failed its planned early-efficacy criteria, including the primary heartburn-severity endpoint. It also discontinued MD-7246 after a Phase II trial failed primary and key secondary endpoints.
- Restructuring: The company planned to reduce its workforce by approximately 100 employees, substantially in Q4 2020. It estimated $15–18 million of related costs, primarily cash severance and benefits; approximately $1.2 million of fixed-asset impairment charges had been recorded by September 30. Management expected savings from the reduction and discontinued-program spending.
- LINZESS: The FDA approved a supplemental label update in September 2020 describing broader effects on abdominal symptoms in IBS-C. Pediatric studies remain ongoing. In January 2020, Ironwood and AbbVie settled patent litigation with Sandoz and Teva concerning generic LINZESS applications.
- COVID-19: In-person promotion was limited and some activities shifted to virtual support; the company reported no significant U.S. LINZESS supply disruption as of the filing. COVID-19 affected IW-3718 trial enrollment and may affect demand, healthcare access, reimbursement, operations and financing. Ironwood reported incremental pandemic-related expenses of approximately $2.1 million for the first nine months.
- Concentration and execution risks: Ironwood relies heavily on AbbVie-linked U.S. LINZESS revenue and on partners and third parties for commercialization, manufacturing and reporting. Other risks include competition, reimbursement and pricing pressure, clinical and regulatory uncertainty, patent challenges and potential supply-chain disruption.
- Guidance: The filing provides no specific revenue or earnings guidance. Management expects to continue investing in LINZESS and GI development, while noting that cash-flow and revenue projections are uncertain. It stated that cash on hand was expected to cover at least the next 12 months of projected operating needs.
Important facts for investors to verify
- Whether LINZESS demand, U.S. collaboration profits and partner-reported sales sustain growth, particularly as in-person promotion and healthcare access evolve.
- Timing, actual cash cost and realized savings from the planned workforce reduction and IW-3718 discontinuation; the $15–18 million estimate was not fully accrued at quarter-end.
- Debt service and refinancing or conversion exposure, including the $120.7 million 2022-note principal and the larger 2024 and 2026 maturities.
- Cash conversion and receivables collection: reported accounts receivable, including long-term receivables, totaled approximately $136.4 million, primarily related to collaborations and API.
- Progress of pediatric LINZESS studies, generic competition and patent protection, and the continuing effects of COVID-19 on sales, trials and supply.